8-K: Current report filing
Published on March 1, 2007
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 21, 2007
Access Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-9314 83-0221517
- --------------------------------------------------------------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
--------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (214) 905-5100
--------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
/ / Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
/ / Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
/ / Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
/ / Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
On February 21, 2007, Access Pharmaceuticals, Inc. issued a press release,
copy of which is attached as Exhibit 99.1 to this report and incorporated
herein by this reference, in which it announced that it had entered into a
non-binding letter of intent to acquire Somanta Pharmaceuticals, Inc.
The information contained herein, including the press release, is not an
offer to sell securities and is not soliciting an offer to buy securities.
If Access Pharmaceuticals, Inc. and Somanta Pharmaceuticals, Inc. enter
into a definitive acquisition agreement, investors are urged to read the
documents relating to the proposed transaction that may be filed from time
to time by either party with the Securities and Exchange Commission.
These documents will contain important information regarding the proposed
transaction and may be obtained after they are filed free of charge at the
Securities and Exchange Commission's website at www.sec.gov.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit Number Description of Exhibit
99.1 Press Release dated February 21, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: March 1, 2007
ACCESS PHARMACEUTICALS, INC.
By:/s/ Stephen B. Thompson
------------------------
Stephen B. Thompson
Vice President and
Chief Financial Officer